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Original Article
Objectives: We aimed to estimate the annual socioeconomic burden of coronary heart disease (CHD) in Korea in 2005, using the Na-
tional Health Insurance (NHI) claims data. 
Methods: A prevalence-based, top-down, cost-of-treatment method was used to assess the direct and indirect costs of CHD (Interna-
tional Classification of Diseases, 10th revision codes of I20-I25), angina pectoris (I20), and myocardial infarction (MI, I21-I23) from a so-
cietal perspective. 
Results: Estimated national spending on CHD in 2005 was $2.52 billion. The majority of the spending was attributable to medical costs 
(53.3%), followed by productivity loss due to morbidity and premature death (33.6%), transportation (8.1%), and informal caregiver 
costs (4.9%). While medical cost was the predominant cost attribute in treating angina (74.3% of the total cost), premature death was 
the largest cost attribute for patients with MI (66.9%). Annual per-capita cost of treating MI, excluding premature death cost, was $3183, 
which is about 2 times higher than the cost for angina ($1556).
Conclusions: The total insurance-covered medical cost ($1.13 billion) of CHD accounted for approximately 6.02% of the total annual 
NHI expenditure. These findings suggest that the current burden of CHD on society is tremendous and that more effective prevention 
strategies are required in Korea. 
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INTRODUCTION
Over the past 3 decades, coronary heart disease (CHD) mor-
tality has fallen by more than 50% in developed countries such 
pISSN 1975-8375 eISSN 2233-4521 
as the United States, Canada, Australia, France, and Japan [1,2]. 
By contrast, recent trends have shown that CHD mortality has 
been rising in many developing or newly developed countries 
including Korea, China, India and other Asian countries [3]. Al-
though the CHD mortality rate in Korea remains among the 
lowest in the world [4], it increased rapidly (by more than 5- to 
6-fold) from 1983 to 2003 [5]. At present, CHD is one of the 
leading causes of death in Korea, and the age of CHD onset is 
conjectured to be younger among Koreans than in the past [6,7]. 
However, the emergence of CHD epidemics in these countries 
has attracted little concern and a limited public health re-
sponse [1,8]. The lack of recognition of the seriousness of the 
CHD impact on individuals and society hinders the implemen-
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tation of more vigorous prevention strategies. Although sever-
al studies of the cost-of-illness of CHD have been carried out in 
industrialized western countries [9,10], few studies have been 
done in Asian countries. A goal of this study was to estimate 
the socioeconomic cost of treating CHD in Korea in 2005. It is 
hoped that increased awareness and knowledge about the 
magnitude and components of economic burden of CHD in 
Korea would influence health policy makers to allocate more 
health care resources and to prioritize the prevention of CHD 
with other public health problems. 
METHODS
Study Design
This was a population-based study designed to examine the 
economic impact of the CHD epidemic in Korea on individuals 
and society as whole. The economic consequences of CHD were 
estimated from a societal perspective using a prevalence-based 
approach, in which the costs of both incident (new) and prev-
alent (pre-existing) cases of CHD are measured within a popu-
lation over a defined period of time [11]. This was a cost-of-
treatment study, examining only the costs associated with 
treating CHD. This study adopted a top-down approach that 
estimated the average cost of treatment for individual patients 
based on the national data. To understand the differences in 
cost patterns according to subtypes of CHD, we performed 
separate cost estimation for angina pectoris and myocardial 
infarction (MI), the most prevalent CHD subtypes in the Kore-
an population. 
Study Cohort and Data Sources
We used the electronic administrative claims records of the 
Korean National Health Insurance (NHI) and Medical Aid (MA) 
program as a major data source to identify study cohorts of 
patients with CHD, angina, or MI, and to track health care ser-
vices provided to patients to treat these conditions during 2005. 
As a mandatory government-run program, the NHI and MA 
claims database contains all medical and prescription drug 
claims for insurance-covered services provided to the entire 
population.
Individuals (N=959 037) aged 20 years or older were includ-
ed in the study cohort if they had at least one insurance claim 
record with a primary or secondary diagnosis of CHD (Interna-
tional Classification of Diseases, 10th revision (ICD-10) codes 
of I20-I25) during 2005. Ten thousand and two claims were ex-
cluded if they had at least one claim containing a diagnosis of 
cancer (ICD-10 code: C00-C97), because treatments for this 
condition are associated with extremely high expenditures. 
CHD-related claims, defined as those with a primary or a sec-
ondary diagnosis of CHD, were extracted for each subject and 
aggregated to produce patient-level information on the total 
CHD-related healthcare utilization and cost. The same meth-
ods were used to identify the study cohorts of CHD subtypes, 
using ICD-10 codes of I20 for angina and I21-I23 for MI [12,13]. 
After cleansing the data sets, we obtained information on 956 
191 patients from 3 741 848 claims for CHD. During the year of 
2005, there were 307 935 claims included as CHD for one out-
patient visit. The number of CHD patients according to diag-
nosis categories after cleansing the data sets is provided in Ta-
ble 1. The information on other costs not included in the NHI 
database was obtained from the Korean National Statistics of-
fice and from the 2001 and 2005 Korean National Health & 
Nutritional Examination Survey (KNHANES) [14]. To estimate 
the indirect cost, we obtained data from the Korean National 
Statistical Office and from the Ministry of Labor [15,16].
Cost Estimation and Data Analysis
The total economic cost of CHD includes direct and indirect 
costs. In this study, direct costs included medical costs and 
transportation costs. Indirect costs consisted of lost opportu-
nity due to morbidity and premature death and informal care 
costs. We estimated the average per-capita costs and the total 
national costs for treating CHD, angina, and MI during 2005 by 
gender and by 5-year age grouping. All costs were expressed 
in 2005 monetary value.
Table 1. The number of treated CHD patients according to 
diagnosis categories 
CHD Angina    MI Others
Primary diagnosis IPD 99 019 62 823 22 447 19 533 
OPD 545 383 419 432 60 056 119 055 
IPD+OPD 568 672 436 842 70 568 130 543 
1st secondary 
diagnosis
IPD 57 839 25 592 8624 25 896 
OPD 568 543 384 674 32 985 190 879 
IPD+OPD 599 593 401 047 40 057 208 842 
Primary diagnosis+ 
1st secondary 
diagnosis
IPD 130 233 84 786 29 597 42 630 
OPD 922 997 691 899 84 485 276 170 
IPD+OPD 956 191 714 101 99 128 299 333 
CHD, coronary heart disease; MI, myocardial infarction; IPD, inpatient depart-
ment; OPD, outpatient department.
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Direct Costs
Direct costs include direct medical costs and transportation 
costs spent to visit healthcare providers. Direct medical costs 
were estimated from spending on inpatient care, outpatient 
care, and prescription costs. The NHI and MA claims data are 
limited in that they provide only information on the medical 
costs for insurance-covered services. Therefore, medical costs 
for non-covered services were estimated on the basis of a 
published report on the proportion of uninsured medical costs 
to the total medical costs spent to treat CHD, which was mea-
sured using medical bills from selected hospitals in Korea in 
2005 [7]. The average proportion of uninsured costs for hospi-
tal admission and outpatient visits associated with CHD was 
estimated as 26.1% and 9.3%, respectively. 
Transportation cost was calculated by multiplying the aver-
age round-trip transportation cost to healthcare institutions 
by the total number of CHD-related visits or admissions per 
year. The average round-trip cost ($18.6 for an outpatient visit 
and $23.6 for a hospital admission, using an exchange rate of 
￦1024 for $1) was obtained from the 3rd KNHANES in 2005. 
Considering that most elderly patients in Korea visit hospitals 
with a caregiver, transportation costs for a caregiver were add-
ed for patients aged 65 years and older. 
Direct costs=medical costs (MC)+transportation costs (TC)
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i=   1 if 20-24 years old, 2 if 25-29 years old, … , 14 if 85 or 
over
j=   1 if male, 2 if female
α=   proportion of uninsured costs among the total medical 
costs for inpatient care 
β=   proportion of uninsured costs among the total medical 
costs for outpatient care
Eij=   insured medical costs for inpatient care
OEij=   insured medical costs for outpatient care 
Mij=  prescription drug costs
Oij=   number of outpatient visits 
Iij=   number of hospital admissions 
OMij=   average transportation cost for an outpatient visit 
IMij=   average transportation cost for a hospital admission 
Indirect Cost
The indirect costs were calculated as productivity losses by 
patients and caregivers. According to the human capital ap-
proach, the monetary value of opportunity costs for CHD mor-
bidity and mortality was quantified as productivity loss due to 
absence from work caused by hospitalization and outpatient 
visits as well as premature death [17]. Productivity loss due to 
CHD-related morbidity was calculated by multiplying the aver-
age daily or hourly wage by days of hospitalization or hours 
spent in outpatient visits (assumed as one third of the day) at-
tributable to CHD [18,19]. Premature death costs were the ex-
pected value of an individual’s future earnings during the po-
tential years of life lost (PYLL) [15], which was defined as a dis-
crepancy between the life expectancy and the age of death as 
obtained from the Korean life table [20]. The monetary value 
of the future income loss for the period after 65 years of age 
was counted as zero, because Korean people generally retire 
from work at age 65. Expected future earnings were discount-
ed by 5% annually to reflect the present value of future pro-
ductivity [21]. Sensitivity analysis was conducted with a re-
laxed assumption on the productivity loss due to premature 
death from CHD over 65 years of age.
The opportunity cost for informal caregivers’ time spent to 
take care of patients with CHD was estimated to be a product 
of days in hospitalization or hours spent for outpatient visits 
attributable to CHD and the average daily wage ($55.48) of 
women aged 20 to 50 years. This is based on the fact that, in 
Korean culture, in general, young female family members serve 
as primary caregivers when family members are sick. Consid-
ering that most elderly patients in Korea visit the hospital ac-
companied by a caregiver, one third of the opportunity cost 
for a caregiver was added to outpatient visits for those over 65 
years old. 
Indirect costs=productivity loss due to morbidity (PL)+
informal caregiver costs (IF)+premature death costs (PD) 
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Nij=days in hospitalization 
δ=  non-productivity rate of outpatient care compared to in-
patient care
Oij=number of outpatient visits
Pij=proportion of population being economically active,
yij=average daily earning
IC=average daily informal care costs
t=age of death
τ=number of years after death till 65 years
Fij=number of deaths
Yjt+τ=average yearly earning at t+ τ
γ=discount rate 
RESULTS
Treated Prevalence of Coronary Heart Disease
The total adult population aged 20 years or older diagnosed 
with and treated for CHD during 2005 was 959 037 (462 231 
men and 496 806 women), and the treated prevalence of CHD 
among adults aged 20 years or older was 2454 per 100 000 
(Table 2). Figure 1 presents the overall age- and gender-specif-
ic treated prevalence of CHD, angina, and MI among the adult 
Korean population. The proportion of the adult population 
with CHD, angina, or MI was estimated to be 2.45% (male, 
2.38%; female, 2.53%), 1.83% (male, 1.78%; female, 1.88%), 
and 0.26% (male, 0.31%; female, 0.20%), respectively. Overall, 
women showed a higher prevalence of CHD and angina than 
men, whereas men had a higher prevalence of MI. For both 
CHD and angina, the prevalence peaked sharply and then de-
clined between the ages of 65 and 69 in men and 70 and 74 in 
women. On the other hand, the prevalence of MI increased 
steadily with age. 
Total National Costs
The total national costs of CHD are provided in Table 3. 
Overall, the annual economic burden of CHD imposed on Ko-
rean society was estimated to be $2.52 billion in 2005. Medical 
cost was the largest component of CHD-related costs, at $1.3 
billion (53.3%), followed by productivity loss due to morbidity 
and mortality (33.6%), transplantation cost (8.1%), and infor-
mal caregiver cost (4.9%) (Figure 2). 
The total national costs associated with angina and MI were 
$1.1 billion and $954 million, accounting for 45.2% and 37.9%, 
Table 2. The treated prevalence (%) of CHD, angina, and MI in 
Korea
Age (y)
CHD Angina MI
Male Female Male Female Male Female
20-24 0.25 0.18 0.20 0.13 0.02 0.02 
25-29 0.28 0.23 0.22 0.17 0.03 0.02 
30-34 0.46 0.32 0.36 0.24 0.06 0.03 
35-39 0.72 0.48 0.55 0.37 0.09 0.03 
40-44 1.23 0.80 0.93 0.61 0.16 0.05 
45-49 2.04 1.57 1.54 1.20 0.26 0.09 
50-54 2.71 2.40 2.03 1.84 0.36 0.13 
55-59 4.28 4.00 3.23 3.06 0.54 0.22 
60-64 5.85 5.96 4.43 4.56 0.72 0.38 
65-69 7.10 7.62 5.33 5.75 0.90 0.58 
70-74 6.94 7.93 5.20 5.88 0.92 0.71 
75-79 6.82 7.68 5.01 5.45 0.96 0.83 
80-84 6.30 6.14 4.44 4.07 1.01 0.82 
85- 5.25 5.24 3.46 3.15 0.93 0.88 
Total 2.38 2.53 1.78 1.88 0.31 0.20
CHD, coronary heart disease; MI, myocardial infarction.
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Figure 1. Prevalence of treated coronary heart disease by 
age and sex in Korea, 2005. CHD, coronary heart disease; MI, 
myocardial infarction.
Table 3. The total national costs ($) of CHD in Korea 
CHD Angina MI
Direct 
cost
Inpatient care cost 509 520 654 265 711 098 174 468 806 
Outpatient care 
cost
833 968 707 580 463 607 91 718 969
Transportation 
cost
203 876 685 141 324 561 13 232 328 
Subtotal 1 547 366 046 987 499 266 279 420 103 
Indirect 
cost
Productivity loss 84 116 116 265 711 098 13 395 806 
Informal care cost 123 094 544 70 566 302 22 697 137 
Premature death 763 835 278 26 590 271 638 326 056 
Subtotal 971 045 938 362 867 670 674 418 999 
Total 2 518 411 984 1 350 366 937 953 839 103 
CHD, coronary heart disease; MI, myocardial infarction.
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respectively, of the total CHD-related costs (Figure 2). A substan-
tial discrepancy existed in the distribution of cost across differ-
ent cost components between the two subtypes of CHD. For 
example, medical cost was the predominant cost of treating 
angina, making up 74.3% ($846 million) of the total cost, in-
cluding 23.3% for inpatient care and 51.0% for outpatient care, 
and the cost of productivity loss due to premature death made 
up the smallest portion ($26.6 million, 2.3%). On the other 
hand, premature death cost was the largest cost component 
for patients with MI ($638 million, 66.9%), while medical costs 
associated with inpatient and outpatient care accounted for 
27.9% ($266.3 million) only.
Figures 3 and 4 showed the distribution of the total national 
direct and indirect costs for each diagnostic category of CHD by 
age and by gender. Direct costs for CHD, angina and MI, showed 
similar patterns in men and women in that they peaked and 
then declined between the ages of 65 and 74, while indirect 
costs for men were much higher than for women across age 
groups. 
Per-capita Cost 
Table 4 presents annual per-capita health care utilization 
and costs for treating CHD, angina and MI by age and gender 
in Korea in 2005. The average annual cost of CHD per patient 
was $1835, and was comprised of 76.6% for medical costs, 
11.6% for transportation costs, 7.0% for informal care costs, 
and 4.8% for productivity loss due to morbidity. 
Because the NHI claims data do not provide information 
about death for individuals, we couldn’t include productivity 
loss cost due to death for person-level data. Therefore, cost of 
Total national cost of CHD=$2.5 billion
Outpatient care
($834 million)
33.1%
Inpatient care
($509.5 million)
20.2%Premature death
($763.8 million)
30.3%
Informal care
($123.1 million)
4.9%
Productivity loss 
($84.1 million) 
3.3% Transportation 
($203.9 million) 
8.1%
Total national cost of angina=$1.1 billion
Inpatient care 
($265.7 million)  
23.3%Transportation 
($141.3 million)  
12.4%
Productivity loss 
($53.4 million) 
4.7%
Informal care 
($70.6 million) 
6.2%
Premature death 
($26.6 million)  
2.3%
Outpatient care 
($580.5 million)  
51.0%
Total national cost of MI=$953.8 million
Inpatient care 
($174.5 million)  
18.3%
Premature death 
($638.3 million)  
66.9%
Informal care 
($22.7 million)  
2.4%
Productivity loss 
($13.4 million)  
1.4%
Transportation 
($13.2 million)  
1.4%
Outpatient care 
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Figure 2. Total national cost of coronary heart disease in Korea in 2005 according to subtype. 
Figure 3. Direct costs of coronary heart disease by age and 
sex, Korea, 2005. Direct costs include direct medical cost (in-
patient care, outpatient care, and prescribed drug treatment) 
and transportation cost. CHD, coronary heart disease; MI, 
myocardial infarction.
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Figure 4. Indirect costs for coronary heart disease by age and 
sex, Korea, 2005. Indirect costs include productivity loss due 
to morbidity and mortality from coronary heart disease and 
informal caregiver time. CHD, coronary heart disease; MI, myo-
cardial infarction.
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premature death was not included in estimates of per-patient 
cost. It was included in the estimation of the total national costs, 
however, by adding the product of the age-and gender-spe-
cific total number of CHD deaths provided by the National 
Mortality Statistics and the estimated future earnings lost due 
to premature death from CHD across age and gender groups. 
Direct costs, productivity loss due to morbidity, and informal 
care giver costs were estimated based on the claims of pa-
tients who had been treated for CHD in 2005. The cost per pa-
tient for these categories, excluding premature death costs, 
was estimated by dividing by the number of CHD treated pa-
tients in 2005. 
The annual per-capita cost of treating angina excluding pre-
mature death cost was $1556, and was comprised of 76.1% for 
medical care costs, 12.7% for transportation costs, 6.3% for in-
formal care costs, and 4.8% for productivity loss due to mor-
bidity. The annual per-capita cost for MI was $3183, which was 
about 2.0 times higher than the cost for angina. Compared to 
Table 4. Annual health care utilization and costs per patient by age and by sex in Korea, 2005
Sex Age (y)
CHD Angina MI
    IP1     OP2 Costs3     IP     OP Costs   IP    OP Costs
Male ≥ 20 10.2 5.0 2093 8.2 4.6 1712 11.1 3.5 3452 
20-24 7.9 1.7 356 6.1 1.7 301 12.6 1.5 600 
25-29 7.9 1.9 477 7.3 1.9 398 7.5 1.7 877 
30-34 7.0 2.3 641 5.9 2.2 487 8.4 2.1 1464 
35-39 7.1 2.9 981 5.7 2.7 747 8.2 2.4 2128 
40-44 8.2 3.5 1358 6.3 3.2 1023 8.8 2.9 2981 
45-49 8.2 4.2 1654 6.7 3.8 1306 9.1 3.3 3323 
50-54 8.6 4.7 2134 6.9 4.3 1752 9.5 3.6 3686 
55-59 9.2 5.1 2288 7.3 4.7 1919 10.9 3.7 3758 
60-64 9.8 5.4 2300 8.1 5.0 1943 11.0 3.8 3673 
65-69 10.5 5.8 2378 8.5 5.4 2022 11.4 3.9 3630 
70-74 11.8 6.1 2452 9.5 5.7 2042 12.4 3.8 3781 
75-79 13.8 6.1 2415 11.7 5.7 2004 13.0 3.9 3519 
80-84 14.4 5.9 2690 11.3 5.6 1869 14.2 3.5 3576 
85- 16.1 5.5 2533 14.9 5.3 1674 13.5 3.4 3341 
Female ≥ 20 11.6 5.2 1596 8.8 4.9 1411 14.0 3.1 2780 
20-24 5.1 1.6 253 4.7 1.6 237 3.5 1.3 283 
25-29 6.7 1.9 337 7.1 1.8 295 7.6 1.4 539 
30-34 6.2 2.1 363 5.6 2.1 324 6.5 1.5 581 
35-39 8.0 2.6 418 6.7 2.5 414 12.4 1.8 958 
40-44 7.4 3.2 634 6.7 3.0 586 9.2 2.1 940 
45-49 8.1 3.8 804 7.1 3.6 756 9.6 2.4 1205 
50-54 8.1 4.4 1189 6.6 4.1 1114 12.1 2.5 1698 
55-59 8.0 4.9 1368 6.6 4.6 1284 11.7 2.8 2125 
60-64 8.4 5.3 1561 7.0 5.0 1437 11.0 3.3 2693 
65-69 9.8 5.9 1899 7.9 5.5 1724 12.7 3.5 3171 
70-74 12.2 6.1 2055 9.3 5.8 1821 13.6 3.6 3368 
75-79 15.2 6.1 2134 11.6 5.7 1803 15.1 3.7 3660 
80-84 18.9 5.8 2050 15.4 5.4 1635 17.1 3.3 3381 
85- 21.0 5.1 1960 18.7 4.9 1476 16.9 3.0 3042 
Total 10.9 5.1 1835 8.5 4.7 1556 12.2 3.4 3183
CHD, coronary heart disease; MI, myocardial infarction.
1IP= inpatient days per patient, total IP was divided by the number of inpatients to determine IP in each age group. 2OP=average number of outpatient visit per pa-
tient, total OP was divided by the number of outpatients to determine OP in each age group. 3Costs ($)=per patient cost, total costs were divided by the number 
of total treated patients to determine per-patient costs in each age group. $1=￦1024 (2005). 
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angina, the proportion of costs for MI occupied by medical 
care is higher (84.4% vs. 76.1%) and consequently the other 
cost components made up a relatively smaller proportion of 
the total cost (4.2% for transportation costs, 7.2% for informal 
care costs, and 4.2% for productivity loss due to morbidity).
Sensitivity Analysis
For the base case analysis, we applied no productivity loss 
for the remaining life expectancy after the age of 65 with a re-
sult in total premature death costs of $764 million, $27 million, 
and $638 million for CHD, angina, and MI, respectively. When 
we applied one half of the annual income of the age group of 
60 to 64 years to the remaining life expectancy after the age of 
65 years, the estimated premature death costs rose to $1153 
million, $54 million, and $945 million for CHD, angina, and MI, 
respectively. The cost of productivity loss, according to CHD 
premature death, was $911.1 million with a 3% discount rate, 
and $646.3 million with a 7% discount rate. The cost of pro-
ductivity loss, according to angina premature death, was $30.6 
million with a 3% discount rate, and $23.4 million with a 7% 
discount rate. The cost of productivity loss, according to MI 
premature death, was $761.9 million with a 3% discount rate, 
and $540.5 million with a 7% discount rate.
DISCUSSION 
The present study is the first attempt to estimate the eco-
nomic burden of overall CHD, angina and MI in Korea using a 
national database. The estimated socioeconomic cost of CHD 
is $2.5 billion, which is equivalent to approximately 0.32% of 
the gross domestic product ($791.5 billion) of Korea in the 
same year (Table 5). The total insurance-covered medical cost 
($1.13 billion) of CHD accounts for approximately 6.02% of the 
total annual NHI expenditure ($18.82 billion in Korea in 2005). 
It is worthwhile to compare the cost of CHD to the cost of oth-
er diseases to help understand the relative economic impact 
of CHD. 
The socioeconomic costs for each of the 5 leading causes of 
death in Korea in 2001 were reported as follows: ￦5595 billion 
($5.5 billion) for malignant neoplasm, ￦1941 billion ($1.8 bil-
lion) for liver disease, ￦1775 billion ($1.7 billion) for cerebro-
vascular disease, ￦1510 billion ($1.5 billion) for heart disease, 
and ￦971 billion ($0.95 billion) for diabetes [22]. According to 
previous studies, the socioeconomic burden of stroke in our 
country for 2005 was approximately ￦3.737 trillion [23], while 
economic costs related to cancer were estimated to be ￦14.1 
trillion [24]. In regards to cancer, the death cost was ￦7.4 tril-
lion (52.6%), which formed a greater portion of the disease 
burden, but in regards to CHD, the medical costs were estimat-
ed to form the largest part, with ￦1.3 trillion (53.3%).
These results confirm that the current economic burden of 
CHD in Korea is substantial and suggest that the prevention of 
CHD may need to be the priority for health care intervention 
in Korea. Prevention strategies should include both public 
health and clinical approaches, target both the general popu-
lation and high-risk groups, and integrate population-based 
risk modification and cost-effective management strategies 
for individuals [1,25].
In Great Britain and the European Union, the dominant di-
rect medical cost for CHD was inpatient care [26]. In Korea, 
however, it was outpatient care, probably due to the high prev-
alence of angina, which is mainly treated on an outpatient ba-
sis. For angina, medical cost for outpatient care was the largest 
cost component, at $580.5 million (51%) (Figure 2), whereas 
lost earnings due to premature death ($638.3 million [66.9%]) 
was the largest cost in the treatment of MI. When the CHD ex-
penditures of OECD nations in 1999 were examined, the em-
ployment/informal care costs formed a larger part than the di-
rect care costs in the United Kingdom, Switzerland, and Cana-
da. On the other hand, direct care costs formed a larger part 
than the employment/informal care costs in Sweden and Ger-
many. According to the CHD cost estimation results of the 
United Kingdom in 2004, the informal care costs from profes-
sional caregivers were valued at £1013 million, which accounts 
for nearly half of the hospital inpatient care costs of £2425 mil-
lion, creating a large burden [27]. 
Increasing mortality trends in young adults have occurred in 
the United States from 1980 to 2002 despite the wide use of 
Table 5. Macroeconomic significance of societal burden of 
CHD in 2005 
% of GDP % of NHE % of NHI
GDP (2005) 791 519 100.00 - -
NHE (2005) 47 491 6.00 100.00 -
NHI (2005) 18 816 2.38 39.62 100.00 
Social costs of CHD 2518 0.32 5.30 13.38 
Direct costs of CHD 1547 0.20 3.26 8.22 
Direct medical costs of CHD 1343 0.17 2.83 7.14 
Unit: $1 million.
CHD, coronary heart disease; GDP, gross domestic product; NHE, national 
health expenditure; NHI, national health insurance.
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evidence-based therapies such as angioplasty, thrombolysis, 
and various medications [28]. Increased premature death rates 
due to CHD in a relatively younger population in Korea would 
erode the national economy due to the loss of work force [6]. 
This suggests that strong public health actions are needed to 
change lifestyle behaviors and to control the various risk fac-
tors associated with CHD [28]. The average annual per-capita 
costs of patients with CHD, angina or MI excluding mortality 
costs were $1835, $1556, and $3183, respectively. The differ-
ence in per-capita costs between angina and MI may be at-
tributable to the difference in the length of hospital stays (8.5 
days vs. 12.1 days), duration of follow-up outpatient visits, 
drug prescription frequency, and intensity of diagnostic tests 
and therapeutic measures. Patients with acute MI are more 
likely to require emergency medical care, surgical care, and 
hospitalization compared to patients with stable angina. These 
findings are similar to previous findings that emergency medi-
cal costs, initial hospitalization rates, and readmission costs are 
higher in patients with acute MI than those with stable angina 
in the United States [29].
Regardless of the subtype of CHD, per-capita costs were 
consistently greater among men than women because of 
higher levels of indirect and direct costs in men across the age 
groups. Since most of the studies calculate indirect costs based 
on the human capital approach, higher indirect costs for men 
can be explained by higher wage rates for men. The human 
capital approach method usually assesses a loss of productivi-
ty with a loss of labor workforce. This approach is limited in 
that it can underestimate the value in productivity reduction 
according to the domestic work and unofficial nursing care 
[30]. Compared to males, the economic participation of females 
is lower, thus, that production loss of domestic workers, which 
is not included in the estimation, can be an important cause 
for the considerable underestimation of the loss in the female 
production costs compared to males. 
On the other hand, higher direct costs for men to treat the 
same type of CHD might be explained by various factors. Sev-
eral studies from other countries have also reported gender 
differences in the prevalence, medical and surgical treatment 
rates, prognosis and manifestation of cardiovascular disease 
[31]. Similar to the results of a meta-analysis of international 
variations across 31 countries, women were found to have a 
10% higher treated prevalence of angina than men [32]. In the 
Framingham study, it was shown that women who had angina 
generally had a good prognosis, whereas angina in men more 
often led to MI [33]. However, the biological, economical, and 
socio-cultural factors for these gender differences are not well-
known yet [31], and further studies are needed to find the rea-
sons for gender discrepancies in Korea. 
This research made use of the claim data of the entire nation 
to estimate the disease costs of CHD, angina, and MI disease, 
which are anticipated to increase in occurrence gradually in 
our country. Due to the characteristics of the disease, where 
there are many cases where it is included as a secondary diag-
nosis, estimations included the burden of the 1st secondary 
diagnosis as well as the primary diagnosis, so it can be used as 
a reference when distributing medical resources. Also, this re-
search estimated the uninsured medical costs by applying the 
uninsured medical costs ratio according to the disease and 
type of medical institution. It is difficult to estimate an accu-
rate uninsured cost value, but it can be a basis for understand-
ing the rough scale of the costs.
This study had several limitations. First, there was difficulty 
in confirming the accuracy of the diagnoses, since the ana-
lyzed data was not derived from clinical settings, but from 
claims data. However, a validation study performed in Korea 
compared the diagnoses derived from the NHI claims data-
base to actual diagnoses in patients’ medical records. For 2003, 
the overall positive predictive value of the diagnoses was re-
ported to be 81.8% in the case of inpatients [34]. Therefore, we 
believe that, overall, the prevalence rates of CHD based on the 
NHI claims data are likely to be an approximation of the true 
rates. Second, this insurance claims-based study limited our 
access to information such as disease severity, co-morbid con-
ditions, past history and specific treatment. Third, a portion of 
estimated socio-economic cost has been underestimated, since 
intangible (psycho-social) costs were not evaluated. When pa-
tients are accompanied with cancer, stroke, high blood pres-
sure, diabetes, or hyperlipidemia, CHD can be recorded as a 
secondary diagnosis in the clinical scene. This study regarded 
CHD patients as those who had CHD as their primary diagno-
sis, as well as those who received one occurrence of medical 
treatment in the clinic for CHD as their 1st secondary diagno-
sis. Therefore, in cases including patients who were confirmed 
to be none CHD patients, there is a possibility that the medical 
cost was overly estimated. However, in order to reduce the 
possibility of overestimation, claims of CHD after the 1st sec-
ondary diagnosis, cases with accompanying cancer, and claims 
with medical costs over one billion won were excluded from 
the estimation. In future studies, there is a need to estimate a 
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more accurate CHD burden through the consideration of de-
tailed procedures, surgery related to CHD, or the administra-
tion of medications, as in the previous studies of Europe and 
the United States. 
According to a 2008 report on European Cardiovascular Dis-
ease statistics, the percentages of total health care expenditure 
due to CHD for primary care, outpatient care, inpatient care, 
emergency care and medications were estimated to be 2.70% 
in the United Kingdom, 3.20% in Germany, 3.08% in the Czech 
Republic, and 2.05% in Hungary in 2006 [35]. It was estimated 
to be 2.83% of the total health care expenditure in Korea dur-
ing 2005. It is meaningful that the percentages of the health 
care cost of CHD were not much different to those of European 
countries. It implies that Korean society shoulders an enormous 
economic burden comparable to those in developed countries 
and more effective prevention strategies are required. 
In summary, the annual total national costs of CHD, angina, 
and MI in Korea were estimated to be $2.52 billion, $1.1 billion, 
and $954 million in 2005, respectively. Our study results pro-
vide strong evidence of the need to develop national policy to 
effectively prevent CHD in Korea. We found that angina and 
MI, which are subsets of CHD, have different distribution pat-
terns of per-patient and societal cost of disease treatment ac-
cording to gender and age. Better preventive policies for CHD 
can be instituted with a more accurate predictable outcome 
when CHD is subdivided into angina and MI and when dis-
ease-specific cost factors are estimated according to sex, age, 
and per-patient cost. It is our hope that an increased awareness 
of the magnitude and specific components of the economic 
burden of CHD in Korea will influence health policy makers to 
allocate more health care resources to CHD and to prioritize its 
prevention.
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